Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 749

1.

Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese Zucker rats.

Rivera L, Morón R, Sánchez M, Zarzuelo A, Galisteo M.

Obesity (Silver Spring). 2008 Sep;16(9):2081-7. doi: 10.1038/oby.2008.315.

2.
3.

Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats.

Rivera L, Morón R, Zarzuelo A, Galisteo M.

Biochem Pharmacol. 2009 Mar 15;77(6):1053-63. doi: 10.1016/j.bcp.2008.11.027. Epub 2008 Dec 3.

PMID:
19100718
4.

Water-soluble rice bran enzymatic extract attenuates dyslipidemia, hypertension and insulin resistance in obese Zucker rats.

Justo ML, Rodriguez-Rodriguez R, Claro CM, Alvarez de Sotomayor M, Parrado J, Herrera MD.

Eur J Nutr. 2013 Mar;52(2):789-97. doi: 10.1007/s00394-012-0385-6. Epub 2012 Jun 4.

PMID:
22661284
5.

Tesaglitazar, a dual PPAR{alpha}/{gamma} agonist, ameliorates glucose and lipid intolerance in obese Zucker rats.

Oakes ND, Thalén P, Hultstrand T, Jacinto S, Camejo G, Wallin B, Ljung B.

Am J Physiol Regul Integr Comp Physiol. 2005 Oct;289(4):R938-46.

7.

Fat depot-specific expression of adiponectin is impaired in Zucker fatty rats.

Altomonte J, Harbaran S, Richter A, Dong H.

Metabolism. 2003 Aug;52(8):958-63.

PMID:
12898458
8.

Additional effect of visceral fat resection in an obese rat model of gastric banding.

Endo Y, Ohta M, Hirashita T, Eguchi H, Kai S, Kitano S.

Obes Surg. 2009 Jun;19(6):777-82. doi: 10.1007/s11695-008-9613-9. Epub 2008 Jun 26.

PMID:
18581189
9.

Resistin and adiponectin expression in visceral fat of obese rats: effect of weight loss.

Milan G, Granzotto M, Scarda A, Calcagno A, Pagano C, Federspil G, Vettor R.

Obes Res. 2002 Nov;10(11):1095-103.

10.

Effects of combined olmesartan and pravastatin on glucose intolerance and cardiovascular remodeling in a metabolic-syndrome model.

Mizukawa M, Ohmori K, Obayashi A, Ishihara Y, Yoshida J, Noma T, Yukiiri K, Kosaka H, Kohno M.

Hypertens Res. 2009 Jul;32(7):617-24. doi: 10.1038/hr.2009.63. Epub 2009 May 22.

PMID:
19461650
11.

The prostacyclin analog beraprost sodium ameliorates characteristics of metabolic syndrome in obese Zucker (fatty) rats.

Sato N, Kaneko M, Tamura M, Kurumatani H.

Diabetes. 2010 Apr;59(4):1092-100. doi: 10.2337/db09-1432. Epub 2010 Jan 12.

12.
13.
14.

Exercise enhances vasorelaxation in experimental obesity associated hypertension.

Arvola P, Wu X, Kähönen M, Mäkynen H, Riutta A, Mucha I, Solakivi T, Kainulainen H, Pörsti I.

Cardiovasc Res. 1999 Sep;43(4):992-1002.

PMID:
10615427
15.

Endocrine, metabolic and cardioprotective effects of hexarelin in obese Zucker rats.

De Gennaro-Colonna V, Rossoni G, Cocchi D, Rigamonti AE, Berti F, Muller EE.

J Endocrinol. 2000 Sep;166(3):529-36.

16.

Effect of adrenalectomy and glucocorticoid replacement on development of obesity.

Freedman MR, Horwitz BA, Stern JS.

Am J Physiol. 1986 Apr;250(4 Pt 2):R595-607.

PMID:
3515971
17.

Impaired in vivo venous constriction in conscious obese Zucker rats with metabolic syndrome.

Song D, Hutchings SR, Pang CC.

Naunyn Schmiedebergs Arch Pharmacol. 2006 Sep;373(6):451-6. Epub 2006 Aug 31.

PMID:
16944103
18.

Lack of beneficial metabolic effects of quercetin in adult spontaneously hypertensive rats.

Romero M, Jiménez R, Hurtado B, Moreno JM, Rodríguez-Gómez I, López-Sepúlveda R, Zarzuelo A, Pérez-Vizcaino F, Tamargo J, Vargas F, Duarte J.

Eur J Pharmacol. 2010 Feb 10;627(1-3):242-50. doi: 10.1016/j.ejphar.2009.11.006. Epub 2009 Nov 10.

PMID:
19903466
20.

Supplemental Content

Support Center